CANCER HOSPITAL CHINESE ACADEMY OF MEDICAL SCIENCES
National Cancer Center · North China
PD-L1 VENTANA PD-L1 (SP263)
VENTANA Platform
NMPA-approved workflow
NMPAReimbursed
Jianji™ CDx Intelligence Platform
v1.0Powered byBYTEclt Consulting
National Coverage Command
NSCLC China PD-L1 IHC Laboratory Intelligence Map
Loading map…
Segment Metrics
Median TAT
4 Days
Segment median
Market Coverage
80%
~80% core national volume
Est. National Volume
56,000
est. tests / month
Provincial Reach
19 / 31
Active regions registered
Intelligence Explorer
Market Analytics
Real-Time CDx MatrixActive Institutions
77
Provinces Covered
19
Dominant Platform
VENTANA
Top Region
East China
/ 01Primary Intelligence
Platform Concentration
Market Share86%
DominantVENTANA
VENTANA
DAKO
VENTANA
66 inst86%
DAKO
8 inst10%
LEICA
3 inst4%
Regional Intelligence Matrix
Network ConcentrationRKREGIONHEATSHAREINST
01East China
40%31 inst
02North China
21%16 inst
03South China
12%9 inst
04West China
12%9 inst
05Central China
10%8 inst
06Northeast China
5%4 inst
/ 02Operational Metrics
Methodology Distribution
77
Total
Methodologies
PD-L1 IHC 22C3
54%VENTANA PD-L1 (SP263)
25%mAb clone E1L3N
14%Monoclonal Mouse Anti-Human PD-L1 Clone 22C3 (Dako)
3%AmoyDx® PD-L1 (E1L3N)
3%mAb clone MXR003
1%TAT Distribution (%)
12%12%2 Days
40%40%3 Days
9%9%4 Days
39%39%5 Days
/ 03
Curated intelligence · 9 highlightedFeatured Testing Institutions
BEIJING CANCER HOSPITAL
National Cancer Center · North China
PD-L1 22C3
VENTANA Platform
NMPA-approved workflow
NMPAReimbursed
FUDAN UNIVERSITY SHANGHAI CANCER CENTER
National Cancer Center · East China
PD-L1 Monoclonal Mouse Anti-Human PD-L1 Clone 22C3 (Dako)
VENTANA Platform
NMPA-approved workflow
NMPAReimbursed
SUN YAT-SEN UNIVERSITY CANCER CENTER
National Cancer Center · South China
PD-L1 22C3
VENTANA Platform
NMPA-approved workflow
NMPAReimbursed
TIANJIN MEDICAL UNIVERSITY CANCER HOSPITAL, CANCER MOLECULAR DIAGNOSTICS CORE
National Cancer Center · North China
PD-L1 22C3
VENTANA Platform
NMPA-approved workflow
NMPAReimbursed
CANCER HOSPITAL CHINESE ACADEMY OF MEDICAL SCIENCES
National Cancer Center · North China
PD-L1 22C3
VENTANA Platform
NMPA-approved workflow
NMPAReimbursed
CHINA PLA GENERAL HOSPITAL
Teaching Hospital · North China
PD-L1 VENTANA PD-L1 (SP263)
VENTANA Platform
NMPA-approved workflow
NMPAReimbursed
PEKING UNION MEDICAL COLLEGE HOSPITAL
Teaching Hospital · North China
PD-L1 22C3
VENTANA Platform
NMPA-approved workflow
NMPAReimbursed
PEKING UNIVERSITY PEOPLE'S HOSPITAL
Teaching Hospital · North China
PD-L1 VENTANA PD-L1 (SP263)
VENTANA Platform
NMPA-approved workflow
NMPAReimbursed
Market Intelligence Notes
Analyst brief · rule-based live commentary
- geography | province-level | medium confidence▸
East China remains the primary testing cluster, accounting for 40% of participating institutions, while Beijing, Shanghai and Guangdong continue to anchor national testing capacity.
- geography | province-level | medium confidence▸
Testing coverage remains uneven across inland provinces, several of which report only a single participating institution.
- general | mixed | medium confidence▸
Teaching hospital pathology laboratories remain the dominant testing setting across participating institutions.
- general | mixed | medium confidence▸
Commercial laboratory participation remains concentrated in major metropolitan regions.
- platform | institution-level | medium confidence▸
VENTANA remains the dominant testing platform, used by 86% of participating institutions.
- regulatory | assay-entry-level | high confidence▸
NMPA-approved assays account for the majority of classified reported testing workflows in the selected segment.
Supporting metric: NMPA 83%, LDT 0%, RUO 17%, 75 classified assay entries, 97% classification coverage
- regulatory | assay-entry-level | high confidence▸
RUO-classified assay usage shows measurable presence across the selected network view.
Supporting metric: RUO 17% of classified assay entries
- reimbursement | institution-level | high confidence▸
Reimbursement coverage is established across the selected segment, although non-reimbursed institutions remain present in the network.
Supporting metric: 59 / 77 institutions reimbursed, 77%
- reimbursement | province-level | high confidence▸
Provincial reimbursement coverage remains heterogeneous across the selected market view.
Supporting metric: 13 fully covered, 0 partially covered, 6 uncovered provinces
- reimbursement | mixed | high confidence▸
Reported reimbursement pricing shows high variability, indicating materially different payment levels across reported samples.
Supporting metric: 59 price samples, median ¥1350, range ¥450–¥2447, 5.4x spread
- reimbursement | institution-level | high confidence▸
Tier-1 city institutions show higher reimbursement coverage than non-tier-1 institutions in the selected segment.
Supporting metric: Tier-1: 32 / 32 covered (100%), non-tier-1: 27 / 45 covered (60%), gap 40 pp
- scoring | institution-level | high confidence▸
TPS-only remains the largest scoring reporting pattern, while TPS+CPS co-reporting is observed as a distinct lab-level reporting category in the selected segment.
Supporting metric: TPS-only 79%, TPS+CPS 14%, CPS-only 3%, IC 0%, TC 4%, 77 classified labs with scoring data, 100% classification coverage